Skip Navigation LinksHome > February 2014 - Volume 48 - Issue 2 > Hepatitis C Direct-acting Antiviral Agents: Changing the Par...
Journal of Clinical Gastroenterology:
doi: 10.1097/MCG.0000000000000010
Clinical Reviews

Hepatitis C Direct-acting Antiviral Agents: Changing the Paradigm of Hepatitis C Treatment in HIV-infected Patients

Martel-Laferrière, Valérie MD; Bichoupan, Kian MS; Dieterich, Douglas T. MD

Collapse Box

Abstract

Hepatitis C virus (HCV)–related liver disease is a major source of mortality in HIV-infected patients. Approximately one third of all patients with HIV are co-infected with HCV. Patients co-infected with HIV/HCV have shown lower rates of sustained virologic response with pegylated-interferon and weight-based ribavirin as well as more rapid progression of fibrosis than those with HCV mono-infection. Several direct-acting antiviral agents (DAAs), developed originally for HCV mono-infection, are being reevaluated for HIV/HCV co-infection. In addition, entirely new DAAs are being developed, including, interferon-free regimens with fewer side effects, allowing novel treatment opportunities for difficult-to-treat patients. In order for HCV DAAs to be successfully used in the HIV/HCV co-infected population several hurdles must be overcome, including adverse event management and drug-drug interactions. The aim of this review is to discuss the results of trials for new HCV therapies being developed for HIV/HCV co-infected patients and the impact of interferon-free regimens on treatment in the future.

© 2014 by Lippincott Williams & Wilkins

Login

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.